Spero Therapeutics, Inc.

SPRO

US84833T1034

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.46 ^USD	+2.10%		+4.29%	-0.68%

Mar. 13	Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Mar. 13	Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Tamara Joseph Steps Down as Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc, Effective as of March 6, 2024

February 09, 2024 at 04:05 pm EST

Tamara Joseph, the Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc., is stepping down from that position to pursue other interests, effective as of March 6, 2024.

Latest news about Spero Therapeutics, Inc.

Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q4 Revenue $73.5M, vs. Street Est of $18.6M	Mar. 13	MT
Spero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Tamara Joseph Steps Down as Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc, Effective as of March 6, 2024	Feb. 09	CI
Spero Therapeutics Says It Has Enough Funds to Continue Operations Into Late 2025	Jan. 05	MT
Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections	Jan. 02	CI
Transcript : Spero Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q3 Revenue $25.5M, vs. Street Est of $15M	Nov. 13	MT
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Spero Therapeutics Appoints Esther Rajavelu Chief Financial Officer	Nov. 01	MT
Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer	Nov. 01	CI
Spero Therapeutics, Inc. Announces Chief Financial Officer Changes	Nov. 01	CI
HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	23-08-14	MT
Transcript : Spero Therapeutics, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q2 Revenue $2.7M, vs. Street Est of $1.08M	23-08-10	MT
Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Spero Therapeutics Shares Rise 14% After Special Protocol Assessment Agreement With FDA	23-07-31	DJ
Spero Therapeutics in Special Protocol Assessment Agreement for Phase 3 Trial of Tebipenem HBr	23-07-31	DJ
Spero Therapeutics Announces Special Protocol Assessment Agreement with Fda for Phase 3 Pivot-Po Trial of Tebipenem Hbr	23-07-31	CI
Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Growth Index	23-06-23	CI
Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from Russell Microcap Value Index	23-06-23	CI
Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Index	23-06-23	CI
Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from Russell 3000E Value Index	23-06-23	CI
Spero Therapeutics Names Satyavrat Shukla Chief Executive	23-06-14	MT

Chart Spero Therapeutics, Inc.

Duration

Period

More charts

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Spero Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.46 USD

Average target price

7.5 USD

Spread / Average Target

+413.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SPERO THERAPEUTICS, INC.	-0.68%	78.68M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Biotechnology & Medical Research

Tamara Joseph Steps Down as Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc, Effective as of March 6, 2024

Latest news about Spero Therapeutics, Inc.

Chart Spero Therapeutics, Inc.

Company Profile

Income Statement Evolution

Ratings for Spero Therapeutics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs